

《子宮頸癌放射治療共識》

一、治療範圍

1. 子宮頸腫瘤
2. 陰道截端及復發高風險範圍
3. 骨盆腔內淋巴轉移病灶
4. 骨盆腔高風險淋巴轉移範圍
5. 腹腔主動脈旁淋巴轉移病灶
6. 腹腔主動脈旁高風險淋巴轉移範圍

二、治療劑量 / 次數

▲ 體外放射治療

1. 總劑量：無接受手術：早期單獨體外照射需超過等效劑量 (EQD2)80Gy、局部晚期單獨外照射需超過等效劑量 (EQD2)85Gy，或體外照射 45~50.4Gy 後合併近接治療；對於巨觀淋巴轉移病灶，總劑量可至 55-70Gy。接受手術：體外照射 45~50.4Gy 後依風險因子局部加強 5-10 Gy。
2. 分次劑量：1.8~2.0Gy

▲ 近接放射治療

1. 無手術切除之子宮頸癌病人，除體外放射治療外，另以遠端遙控後荷式近接治療機 (remote after-loading brachytherapy)，採用高劑量率 Ir-192 射源，進行子宮腔內治療 (intra-cavitary brachytherapy)，4-6Gy x 4~6 次、每週 2-3 次。
2. 手術切除之子宮頸癌病人，除體外放射治療外，對於陰道穹隆 (vaginal cuff) 距離不足或陰道殘餘腫瘤病人，另以遠端遙控後荷式近接治療機 (remote after-loading brachytherapy)，採用高劑量率 Ir-192 射源，進行陰道腔內治療 (intra-vaginal brachytherapy)，4-6Gy x 2~4 次、每週 2-3 次。

三、治療方式：

使用強度調控放射治療技術，包含弧形及螺旋放射規畫，可考慮搭配影像導引治療，治療選擇可使用同步照射高與

低危險部位的方式或先給予整個照射部位部份劑量照射後，再針對高危險部位加強劑量。

四、參考文獻：

1. NCCN clinical practice guidelines in oncology-Cervical cancer. Version 4. 2024.
2. Beriwal S, Gan GN, Heron DE, et al. Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer. *Int J RadiatOncolBiolPhys* 2007;68:166-171.
3. Chen M-F, Tseng C-J, Tseng C-C, et al. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. *Int J RadiatOncolBiolPhys* 2007;67:1438-1444.
4. Taylor et al. An Atlas of the Pelvic Lymph Node Regions to Aid Radiotherapy Target Volume Definition. *Clinical Oncology* 2007;19:542-50
5. Willett CG, et al. Principles and Practice of Radiation Oncology. 5th edition: Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 1532-1609.
6. Small W, Mell LK, Anderson P, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. *Int J RadiatOncolBiolPhys* 2008;71:428-434.
7. Erickson-Whitmann B, Rownd J, Khater K. Biologic and physical aspects of radiation oncology. In: barakat R, Markman M, Randall M, eds. Principles and Practice of Gynecology Oncology, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2009: 325-380.
8. Kim JY, Kim JY, Kim JH, et al: Curative chemoradiotherapy in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph node metastases. *Int J RadiatOncolBiolPhys* 84:741-7, 2012
9. Wu SY, Huang EY, Chanchien CC, et al: Prognostic factors associated with radiotherapy for cervical cancer with computed tomography-detected para-aortic lymph node metastasis. *J Radiat Res*, 2013
10. Nikola C, Alexandros T, Coya T, et al: Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer. *Radiat Oncol*. 2015; 10: 240
11. QUANTEC

《子宮內膜癌放射治療共識》

一、治療範圍

1. 術後陰道截端及近側黏膜
2. 術後殘餘腫瘤 (乳突漿液細胞癌、亮細胞癌或癌性肉瘤)
3. 骨盆腔高風險淋巴轉移範圍

二、治療劑量 / 次數

▲ 體外放射治療

1. 總劑量：45~50.4Gy
2. 殘餘腫瘤追加劑量：10~16Gy
3. 分次劑量：1.8~2.0Gy

▲ 陰道腔內近接放射線治療

1. 骨盆腔放射治療後追加：陰道黏膜接受 4-6Gy x 2~4 次。
2. 只接受陰道腔內治療：陰道黏膜接受 6Gy x 5 次或陰道黏膜下 5mm 接受 7Gy x3 或 5.5Gy x4。

三、治療方式：

使用立體順型與強度調控放射治療技術，包含弧形及螺旋放射規畫，可考慮搭配影像導引治療，治療選擇可使用同步照射高與低危險部位的方式或先給予整個照射部位部份劑量照射後，再針對高危險部位加強劑量。

四、參考文獻：

1. NCCN clinical practice guidelines in oncology for uterine neoplasms, 2024 version 3.
2. Aalders J, Abeler V, Kolstad P, et al. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Clinical and histopathologic study of 540 patients. Obstet Gynecol 1980; 56:419-427.
3. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study. Gynecol Oncol 1991; 40:55-65.
4. Kadar N, Homesley HD, Malfetano JH. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if

- there is other evidence of extrauterine disease. *Gynecol Oncol* 1992; 46:145-149.
5. Fishman DA, Roberts KB, Chambers JT, et al. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma of the endometrium. *Gynecol Oncol* 1996; 61:189-196.
 6. Murphy KT, Rotmensch J, Yamada SD, Mundt AJ. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. *Int J Radiat Oncol Biol Phys* 2003; 55 (5) :1272-1276.
 7. Harkenrider MW, Abu-Rustum N, Albuquerque K, et al. Radiation Therapy for Endometrial Cancer: An American Society for Radiation Oncology Clinical Practice Guideline, *Practical Radiation Oncology*, Volume 13, Issue 1, 41 - 65